COMPANY
Metavention
Metavention is conducting clinical studies evaluating the safety and benefits of renal denervation using our iRF Denervation System in patients with high blood pressure. From company website Source · Oct 12, 2026
Timeline
- Trial start Not phased (device or behavioral study): Multi-Organ Denervation With the iRF System to RedUce Sympathetic Drive source ↗
- Trial start Not phased (device or behavioral study): Evaluation of the Integrated Radio Frequency Denervation System for the Treatment of Hypertension source ↗
- Trial start Not phased (device or behavioral study): Evaluation of the Integrated Radio Frequency Denervation System to Improve Glycemic Control in Type 2 Diabetic Subjects source ↗
- Trial start Not phased (device or behavioral study): COMPLEMENT Study- A First in Human Study of Metabolic Neuromodulation Therapy source ↗
Clinical trials (lead sponsor) 4
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT04285554 | Evaluation of the Integrated Radio Frequency Denervation System to Improve Glycemic Control in Type 2 Diabetic Subjects | Not phased (device or behavioral study) | Completed | Jul 28, 2020 | Mar 2, 2022 (actual) |
| NCT04740723 | Evaluation of the Integrated Radio Frequency Denervation System for the Treatment of Hypertension | Not phased (device or behavioral study) | Completed | Feb 6, 2021 | Oct 20, 2021 (actual) |
| NCT04917393 | Multi-Organ Denervation With the iRF System to RedUce Sympathetic Drive | Not phased (device or behavioral study) | Unknown status (ClinicalTrials.gov) | Sep 13, 2021 | Oct 1, 2022 (estimated) |
| NCT02278068 | COMPLEMENT Study- A First in Human Study of Metabolic Neuromodulation Therapy | Not phased (device or behavioral study) | Completed | 2014-10 | 2019-05 (actual) |